Table 2 Response data

From: Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

Study

6-Month PFS % (95% CI)

Median PFS months (95% CI)

Median OS months (95% CI)

% Responders (all partial)

% Stable disease

% Responders+stable disease

TMZ+IFN; n=34

31 (16–54)a

3.6 (3.0–6.3)

7.2 (5.3–10.6)

4/34 (12%)

18/34 (53%)

22/34 (65%)

TMZ+PEG; n=29

38 (24–64)a

4.4 (2.4–6.5)

10.0 (7.8–14.3)

1/29 (3%)

17/29 (57%)

18/29 (62%)

  1. aNumbers are n=29 for TMZ+IFN and n=26 for TMZ+PEG due to patients being not evaluable for response.
Back to article page